Study #2024-1058
A phase 2, open-label, randomized, multicenter study to evaluate the safety and efficacy of Axatilimab in combination with Ruxolitinib in participants with newly diagnosed chronic Graft-Versus-Host disease.
MD Anderson Study Status
Enrolling
Treatment Agent
Axatilimab, Ruxolitinib, Corticosteroids
Description
This study will be conducted to determine the preliminary efficacy of axatilimab in combination with ruxolitinib and to assess the contribution of axatilimab to the combination treatment effect in participants with cGVHD.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Chronic Graft-versus-host-disease
Study phase:
Phase II
Physician name:
Amin Alousi
Department:
Stem Cell Transplantation
For general questions about clinical trials:
1-855-773-0951
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.